Expert Interview
A second opinion: Discussing the potential of Prevnar20, a vaccine approved for the prevention of invasive disease caused by 20 Streptococcus pneumoniae strains in individuals 6 weeks and older.
Ticker(s): PFEInsitution: Self-employed
- Assistant professor of medicine and self-employed pediatrician
- Currently use Prevnar 13 and would consider a change to Prevnar 20
- Familiar with the data on Prevnar 20
- Sees 20 patients with autism
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
